Celltrion Pharm
Celltrion Pharm Inc is a South Korean pharmaceutical company engaged in the manufacturing, marketing, and distribution of chemical prescription drugs and biosimilars. The company produces liver disease treatments, cardiovascular medicines, metabolic therapies, and distributes Celltrion's biosimilar antibody products like Remsima and Truxima. Main revenue drivers comprise domestic commercial sales of prescription chemical pharmaceuticals, generic medicines, and biosimilar therapies. Celltrion Pharm serves hospital networks, medical clinics, prescription pharmacies, and healthcare patients across South Korea. The company holds a market-leading position in South Korea's domestic liver disease therapeutic market and biosimilar distribution. Headquartered in Cheongju, North Chungcheong, South Korea, Celltrion Pharm Inc is listed on the KOSDAQ market.
2 of the funds FundTelligence covers report a position in Celltrion Pharm.
- Legal name
- Celltrion Pharm Inc
- Sector
- Health Care
- Country
- South Korea
- Funds holding it
- 2
Funds holding Celltrion Pharm
- BlackRock iShares MSCI EM IMI Screened UCITS ETF — BlackRock · 0.01 % (full portfolio disclosed, October 2026)
- Storebrand Indeks Nye Markeder — Storebrand · 0.0 % (full portfolio disclosed, October 2026)